

a.) Amendment to the Specification:

Please amend the paragraph at page 7, lines 19-26 to read as follows.

$\text{-NR}^{8a}\text{R}^{8b}$ ~~(wherein R^{8a} and R^{8b}~~ (wherein R^{8a} and R^{8b} may be the same or different and each represent a hydrogen atom, substituted or unsubstituted lower alkyl, lower cycloalkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted aroyl, lower alkoxycarbonyl, formyl, or

Please amend the paragraph at page 8, lines 11-12 to read as follows:

$\text{-NR}^{8a}\text{R}^{8b}$ ~~(wherein R^{8a} and R^{8b}~~ (wherein R^{8a} and R^{8b} have the same meanings as defined above, respectively); and

Please amend the paragraph at page 9, lines 14-21 to read as follows:

(3) The [1,2,4]triazolo[1,5-c]pyrimidine derivative according to the above (1), wherein R^3 is aryl substituted with a substituent selected from the group consisting of $\text{-CH}_2\text{NHR}^{4a}$ (wherein R^{4a} has the same meaning as defined above), $\text{-(CH}_2\text{)}_{nb}$, $\text{C(R}^{6a}\text{)(R}^{6b}\text{)(OR}^7\text{)}$ (wherein nb , R^{6a} , R^{6b} and R^7 have the same meanings as defined above, respectively), and $\text{-NR}^{8a}\text{R}^{8b}$ ~~(wherein R^{8a} and R^{8b}~~ (wherein R^{8a} and R^{8b} have the same meanings as defined above, respectively), or a pharmaceutically acceptable salt thereof.

Please amend the paragraph at page 10, lines 4-12 to read as follows.

(6) The [1,2,4]triazolo[1,5-c]pyrimidine derivative according to the above (1), wherein R^3 is an aromatic heterocyclic group substituted with a substituent selected from the group consisting of $-CH_2NR^{4b}R^{4c}$ (wherein R^{4b} and R^{4c} have the same meanings as defined above, respectively), $-(CH_2)_{nb}-C(R^{6a})(R^{6b})(OR^7)$ (wherein nb , R^{6a} , R^{6b} and R^7 have the same meanings as defined above, respectively), and $-NR^{8a}R^{8b}$ (wherein R^{8a} and R^{8b} have the same meanings as defined above, respectively), or a pharmaceutically acceptable salt thereof.

Please amend the paragraph at page 10, lines 19-23 to read as follows.

(8) The [1,2,4]triazolo[1,5-c]pyrimidine derivative according to the above (1), wherein R^3 is an aromatic heterocyclic group substituted with $-NR^{8a}R^{8b}$ (wherein R^{8a} and R^{8b} have the same meanings as defined above, respectively), or a pharmaceutically acceptable salt thereof.

Please amend the paragraph at page 19, lines 10-22 to read as follows.

The substituted aryl, the substituted aroyl, the substituted aromatic heterocyclic group and the substituted aralkyl each have, for example, 1 to 3 substituents which may be the same or different. Specific examples of the substituents include lower alkyl, hydroxy, hydroxy-substituted lower alkyl, halogeno lower alkyl, lower alkoxy, lower alkoxy carbonyl, aryl, aryloxy, aralkyl, aralkyloxy, an aromatic heterocyclic group, halogenoaryloxy, halogenoaralkyloxy, carboxy, carbamoyl, formyl, lower alkanoyl, aroyl,

halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, methylenedioxy, ethylenedioxy, and formyl and equivalents thereof (the equivalents include 1,3-dioxolan-2-yl).

Please amend the paragraph starting at page 19, line 25 and ending at page 20, line 2.

Examples of the substituents in the substituted aryl include $-\text{CH}_2\text{NR}^{4b}\text{R}^{4c}$ (wherein R^{4b} and R^{4c} have the same meanings as defined above, respectively), $-(\text{CH}_2)_{nb}-\text{C}(\text{R}^{6a})(\text{R}^{6b})(\text{OR}^7)$ (wherein nb , R^{6a} , R^{6b} and R^7 have the same meanings as defined above, respectively) and $-\text{NR}^{8a}\text{R}^{8b}$ (~~wherein R^{8b} and R^{8b}~~ wherein R^{8a} and R^{8b} have the same meanings as defined above, respectively), in addition to the above-described examples of the substituents in the substituted aryl.

Please amend the paragraphs starting at page 22, line 8 and ending at page 23, line 1 to read as follows:

Compounds wherein R^1 is furyl, and R^2 is a hydrogen atom are preferable. In addition, compounds wherein R^3 is aryl substituted with a substituent selected from the group consisting of $-\text{CH}_2\text{NHR}^{4a}$ (wherein R^{4a} has the same meaning as defined above), $-(\text{CH}_2)_{nb}-\text{C}(\text{R}^{6a})(\text{R}^{6b})(\text{OR}^7)$ (wherein nb , R^{6a} , R^{6b} and R^7 have the same meanings as defined above, respectively) and $-\text{NR}^{8a}\text{R}^{8b}$ (~~wherein R^{8b} and R^{8b}~~ wherein R^{8a} and R^{8b} have the same meanings as defined above, respectively);

compounds wherein R^3 is an aromatic heterocyclic group substituted with a substituent selected from the group consisting of $-\text{CH}_2\text{NR}^{4b}\text{R}^{4c}$ (wherein R^{4b} and R^{4c} have the same meanings as defined above, respectively), $-(\text{CH}_2)_{nb}-\text{C}(\text{R}^{6a})(\text{R}^{6b})(\text{OR}^7)$ (wherein

nb, R^{6a}, R^{6b} and R⁷ have the same meanings as defined above, respectively) and -NR^{8a}R^{8b} (wherein ~~R^{8b}~~ and ~~R^{8b}~~ (wherein R^{8a} and R^{8b} the same meanings as defined above, respectively);

compounds wherein R³ is aryl substituted with -CH₂NHR^{4a} (wherein R^{4a} has the same meaning as defined above);

compounds wherein R³ is aryl substituted with -(CH₂)_{nb}-C(R^{6a})(R^{6b})(OR⁷) (wherein nb, R^{6a}, R^{6b} and R⁷ have the same meanings as defined above, respectively);

compounds wherein R³ is an aromatic heterocyclic group substituted with -NR^{8a}R^{8b} (wherein ~~R^{8b}~~ and ~~R^{8b}~~ (wherein R^{8a} and R^{8b} have the same meanings as defined above, respectively);

Please replace Table 12 at page 97 with the table below:

Observation items	Score	0	1	2	3	4
Attention		Normal	Decrease	Sleeping tendency		
Observation		Yes	Decrease	No		
Blinking		Normal	Abnormal			
Posture		Normal	Abnormality in trunk, tail or limbs (1 point)			All abnormal
Balance		Normal	Asymmetry	Cannot stand	Drop out	
Reaction		Normal	Decrease	Slow	No	
Utterance		Normal	Decrease	No		
Total	0-17 points					

Please amend the paragraph at page 220, lines 16-25 to read as follows.

The reaction was carried out in a manner similar to that in Example 77 except that N-acetylenediamine was replaced by N-(2-pyridylmethyl)-2,2,2-trifluoroethylamine. Then, the resulting crude product was recrystallized from a mixed solvent of hexane and ethyl acetate to obtain ~~Compound 131~~ Compound 133 (201 mg,

0.475 mmol) as white crystals in a yield of 22%. ^1H NMR (δ ppm, DMSO- d_6 , 80°C): 8.50 (d, $J=3.5$ Hz, 1H), 7.99 (s, 2H), 7.87 (d, $J=0.9$ Hz, 1H), 7.68-7.78 (m, 1H), 7.23-7.35 (m, 2H), 7.17 (d, $J=3.3$ Hz, 1H), 6.99 (brs, 1H), 6.68 (dd, $J=3.3$ Hz, 0.9 Hz, 1H), 4.90 (s, 2H), 4.36 (brs, 2H)